Skip to content

Effect of Ketosis on Pain and Quality of Life in Patients With Lipedema

The Norwegian LIPODIET Study: Effect of Ketosis on Pain and Quality of Life in Patients With Lipedema

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04632810
Acronym
Lipodiet
Enrollment
70
Registered
2020-11-17
Start date
2021-03-22
Completion date
2025-08-11
Last updated
2026-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lipedema

Keywords

Diet therapy, Ketosis, Pain, Weight loss

Brief summary

Lipedema is a female progressive fat disorder, characterized by a symmetrical increase in subcutaneous adipose tissue in the lower extremities with the exception of the waist. The condition is often misdiagnosed and underdiagnosed. The etiology is poorly understood. Affects about 11% of all women and may lead to pain and immobility. The pathophysiology may be related to sex hormones and inflammatory response. Lipedema fat has been reported not to respond to lifestyle changes or bariatric surgery, both in terms of weight loss and symptom reduction; including pain and quality of life. Clinical research on the effect of dietary interventions on lipedema does not exist, but a pilot study with a ketogenic diet showed a significant reduction in pain regardless of weight loss. The aim of the research project will be to investigate whether a ketogenic diet can be a treatment option for patients with lipedema. Therefore, a randomized controlled trial will be conducted to compare the effects of two diets. 1) energy-restricted ketogenic diet and 3) energy-restricted low-fat non-ketogenic diet for 8 weeks. Pain and quality of life will be mesured at start and immediately after the intervention. The hypothesis is that a ketogenic diet may reduce pain and improve quality of life.

Detailed description

Study design RCT comparing a low-energy ketogenic diet to a non-ketogenic low-energy diet (non-keto) in females with lipedema. This study was approved by the Reginal Ethical Committee (REK 93888) All participants have to provided written informed consent in line with the Helsinki Declaration, before entering the study. Participants will be randomized by block randomization with stratification by BMI categories. Study population Females diagnosed with lipedema, aged 18-75 years old, and a BMI between 30-45 kg/m2, will be invited to participate in this study. Participants had to be diagnosed with lipedema by physiotherapists before inclusion. Inclusion criteria includs weight stability for the last three months (±3 kg). Dietary interventions Diets were matched for energy (1200 kcal/day) and protein, but differed in carbohydrate (CHO) and fat content. The dietary plans are adjusted with respect to food preferences, intolerances, and allergies. The participants will be asked not to change their physical activity levels throughout the study period. Compliance Participants will have weekly follow-ups. Participants will be asked to fill out daily food records throughout the intervention period. Ketostix will be used in the weekly follow-ups to measure urinary acetoacetate (AcAc). If the participants in the keto group were outside of ketosis, or participants in the non-keto group in ketosis, \>2 times throughout the study period, they were excluded from the per-protocol (PP) analysis. Outcome variables The following variables were assessed at baseline and at the end of the intervention: Anthropometrics and body composition Height and weight will be measured at baseline. Body composition will be assessed in fasting state with Bioelectrical Impedance Analysis before and after the intervention.. Pain Pain will be assessed with the brief Pain Inventory. The participants rated their pain in a numerical rating scale (NRS), where 0 = no pain and 10 = Worst imaginable pain. The BPI assesses pain intensity: strongest pain, weakest pain, average pain, pain now, pain severity score using an average of pain intensity domains, and pain inference from daily activities, mood, walking, regular work, relationships, sleep and life joy. A pain inference score is also computed as the average of all pain inference domains. Three different questionnaires are used to assess Quality of life. RAND-36. The Impact of Weight on Quality of Life-Lite (IWQOL-Lite) q and the Lymphoedema Quality of Life (LYMQOL).

Interventions

OTHERKetogenic low energy diet

Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 75g (25E%), protein 60 g (20E%), fat 73 g (55E%) in 8 weeks

OTHERnon-ketogenic low energy diet

Participants will follow a low energy diet, with 1200 kcal per day. Carbohydrates 180g (60E%), protein 60 g (20E%), fat 27 g (20E%), in 8 weeks

Sponsors

Helse Nord-Trøndelag HF
Lead SponsorOTHER
Norwegian University of Science and Technology
CollaboratorOTHER
St. Olavs Hospital
CollaboratorOTHER
Vanderbilt University Medical Center
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with lipedema by skilled physical therapists * Body mass index \> 30kg/m2 and \< 45kg/m2 * Stable weight over the last three months (+2-3kg) * Not currently dieting to lose weight * Willing to meet for follow-ups every second week during the intervention * Willing to sign an informed consent before entering the study

Exclusion criteria

* Pregnant or breast feeding * History of infectious diseases * Medication known to affect obesity * Enrolled in any other obesity treatment * Having had bariatric surgery. * Kidney disease is excluded * History of psychological disorders * Not mastering a Scandinavian language * Being mentally disabled * Malign disease * Diabetes * Any disease that leads to dietary advice that is not consistent with intervention advice

Design outcomes

Primary

MeasureTime frameDescription
change in pain intensity8 weeksA difference in mean pain score of 2 units on a continuous scale from 0 to 10 on a visual analog scale (VAS) is considered clinically interesting
change in quality of life8 weeksLikert Scale

Countries

Norway

Contacts

PRINCIPAL_INVESTIGATORSiren Nymo, PhD

Nord-Trøndelag Hospital Trust, Namsos Hospital, Clinic of Surgery

STUDY_DIRECTORHallvard Græslie, md

Nord-Trøndelag Hospital Trust, Namsos Hospital, Clinic of Surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 22, 2026